Patents by Inventor Hongxing Zhou

Hongxing Zhou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20130115215
    Abstract: Described herein is an antibody format, which is amenable to bispecific antibody creation. This format is referred to herein as “Domain Insertion Immunoglobulin G” or “(Di-IgG)”. The Di-IgG molecules are capable of specifically binding two different antigens simultaneously, show high level recombinant expression, and are sufficiently aggregation-free to be amenable to commercial production. Further described herein are, Di-IgG-encoding nucleic acids and vectors, host cells for making Di-IgGs, Di-IgG pharmaceutical compositions, and methods of treatment.
    Type: Application
    Filed: July 14, 2011
    Publication date: May 9, 2013
    Inventor: Hongxing Zhou
  • Publication number: 20120321626
    Abstract: The present disclosure relates generally to multi-specific Fab fusion proteins (MSFP) which comprise an antibody Fab fragment with both N-termini fused to a fusion moiety (fusion moiety A or B). MSFP containing the Fab fragment exhibit significantly reduced binding ability of the Fab fragment to the Fab target. Binding of the Fab to its target is restored when the MSFP is clustered on a cell surface by binding of the fusion moieties to their target. The reduced binding of the Fab to its target, especially when presented on a cell surface in its native state, absent fusion moiety binding provides advantages such as: reduced side effects and allows desirable pharmacological effects of selectivity and specificity in a controlled manner.
    Type: Application
    Filed: May 16, 2012
    Publication date: December 20, 2012
    Applicant: FABION PHARMACEUTICALS, INC.
    Inventor: Hongxing Zhou
  • Publication number: 20120244578
    Abstract: The invention relates to monomeric Fc polypeptides and methods of making and using such polypeptides. The polypeptides comprise substitution of one or more hydrophobic interface residues in the CH3 region with a polar amino acid.
    Type: Application
    Filed: November 22, 2010
    Publication date: September 27, 2012
    Applicant: AMGEN INC.
    Inventors: Gunasekaran Kannan, Hongxing Zhou, Nancy Sun
  • Publication number: 20120116057
    Abstract: The present invention relates to methods of increasing stability and reducing aggregation in compositions comprising antibody Fc molecules and to composition comprising such molecules. Certain amino acid substitutions in the CH3 domain result in increased stability and reduced aggregation of compositions containing polypeptides comprising a CH3 domain, e.g., an antibody or Fc-fusion protein.
    Type: Application
    Filed: June 29, 2010
    Publication date: May 10, 2012
    Applicant: AMGEN INC.
    Inventors: Gunasekaran Kannan, Hongxing Zhou
  • Publication number: 20120039880
    Abstract: The present invention provides compositions and methods relating to human IgG1 and IgG3 Fc-conjugates which are resistant to free-radical mediated fragmentation and aggregation. The present invention also provides compositions and methods for making the Fc-conjugates of the invention.
    Type: Application
    Filed: April 21, 2010
    Publication date: February 16, 2012
    Applicant: AMGEN INC.
    Inventors: Boxu Yan, Zhonghua Hu, Gerd Richard Kleeman, Zachary Adam Yates, Hongxing Zhou
  • Publication number: 20110081361
    Abstract: The present invention relates to antibodies that bind to the IL-4 receptor, fragments, muteins, and derivatives of such antibodies, nucleic acids encoding such antibodies, fragments, muteins and derivatives, and methods of making and using such antibodies, fragments, muteins, derivatives and nucleic acids. Methods for treating medical conditions induced by interleukin-4 involve administering an IL-4 receptor binding antibody, or an IL-4 receptor binding fragment, mutein, or derivative of an IL-4 receptor binding antibody, to a patient afflicted with such a condition. Particular antibodies provided herein include human monoclonal antibodies. Certain of the antibodies inhibit both IL-4-induced and IL-13-induced biological activities.
    Type: Application
    Filed: December 10, 2010
    Publication date: April 7, 2011
    Inventors: Paul J. Carter, Hongxing Zhou
  • Patent number: 7872113
    Abstract: The present invention relates to antibodies that bind to the IL-4 receptor, fragments, muteins, and derivatives of such antibodies, nucleic acids encoding such antibodies, fragments, muteins and derivatives, and methods of making and using such antibodies, fragments, muteins, derivatives and nucleic acids. Methods for treating medical conditions induced by interleukin-4 involve administering an IL-4 receptor binding antibody, or an IL-4 receptor binding fragment, mutein, or derivative of an IL-4 receptor binding antibody, to a patient afflicted with such a condition. Particular antibodies provided herein include human monoclonal antibodies. Certain of the antibodies inhibit both IL-4-induced and IL-13-induced biological activities.
    Type: Grant
    Filed: August 4, 2009
    Date of Patent: January 18, 2011
    Assignee: Immunex Corporation
    Inventors: Paul J. Carter, Hongxing Zhou
  • Publication number: 20100203590
    Abstract: The present invention relates to antibodies that bind to the IL-4 receptor, fragments, muteins, and derivatives of such antibodies, nucleic acids encoding such antibodies, fragments, muteins and derivatives, and methods of making and using such antibodies, fragments, muteins, derivatives and nucleic acids. Methods for treating medical conditions induced by interleukin-4 involve administering an IL-4 receptor binding antibody, or an IL-4 receptor binding fragment, mutein, or derivative of an IL-4 receptor binding antibody, to a patient afflicted with such a condition. Particular antibodies provided herein include human monoclonal antibodies. Certain of the antibodies inhibit both IL-4-induced and IL-13-induced biological activities.
    Type: Application
    Filed: August 4, 2009
    Publication date: August 12, 2010
    Inventors: PAUL J. CARTER, Hongxing Zhou
  • Patent number: 7638606
    Abstract: The present invention relates to antibodies that bind to the IL-4 receptor, fragments, muteins, and derivatives of such antibodies, nucleic acids encoding such antibodies, fragments, muteins and derivatives, and methods of making and using such antibodies, fragments, muteins, derivatives and nucleic acids. Methods for treating medical conditions induced by interleukin-4 involve administering an IL-4 receptor binding antibody, or an IL-4 receptor binding fragment, mutein, or derivative of an IL-4 receptor binding antibody, to a patient afflicted with such a condition. Particular antibodies provided herein include human monoclonal antibodies. Certain of the antibodies inhibit both IL-4-induced and IL-13-induced biological activities.
    Type: Grant
    Filed: November 4, 2004
    Date of Patent: December 29, 2009
    Assignee: Immunex Corporation
    Inventors: Paul J. Carter, Hongxing Zhou
  • Publication number: 20080124340
    Abstract: Antibodies that bind erythropoietin receptor are provided. Methods of making and using such antibodies are also provided. Kits containing such antibodies are also provided.
    Type: Application
    Filed: April 13, 2007
    Publication date: May 29, 2008
    Inventors: Luis G. Borges, Randal R. Ketchem, Ai Ching Lim, Christopher Mehlin, Hongxing Zhou
  • Publication number: 20070274996
    Abstract: The present invention relates to antibodies that bind to the IL-4 receptor, fragments, muteins, and derivatives of such antibodies, nucleic acids encoding such antibodies, fragments, muteins and derivatives, and methods of making and using such antibodies, fragments, muteins, derivatives and nucleic acids. Methods for treating medical conditions induced by interleukin-4 involve administering an IL-4 receptor binding antibody, or an IL-4 receptor binding fragment, mutein, or derivative of an IL-4 receptor binding antibody, to a patient afflicted with such a condition. Particular antibodies provided herein include human monoclonal antibodies. Certain of the antibodies inhibit both IL-4-induced and IL-13-induced biological activities.
    Type: Application
    Filed: November 4, 2004
    Publication date: November 29, 2007
    Applicant: Immunex Corporation
    Inventors: Paul Carter, Hongxing Zhou
  • Publication number: 20050282181
    Abstract: The invention provides methods for screening multimeric antibodies produced by mammalian cells to find those that exhibit a biological function. The methods can be used to screen large numbers of antibodies, which may be cell surface, secreted, or intracellular antibodies. Antibodies can be screened to find those that bind antigen more avidly or those that compete with a ligand that binds to the antigen for binding. Any biological function that can be tested in vitro can be used to screen the antibodies. Nucleic acids encoding the antibodies that exhibit the biological function can be obtained in a number of ways.
    Type: Application
    Filed: December 21, 2004
    Publication date: December 22, 2005
    Inventors: Wei Yan, Wenyan Shen, Hongxing Zhou, Chen Zhou, David Cosman, Paul Carter, Francis Martin
  • Publication number: 20050112694
    Abstract: The present invention relates to antibodies that bind to the IL-4 receptor, fragments, muteins, and derivatives of such antibodies, nucleic acids encoding such antibodies, fragments, muteins and derivatives, and methods of making and using such antibodies, fragments, muteins, derivatives and nucleic acids. Methods for treating medical conditions induced by interleukin-4 involve administering an IL-4 receptor binding antibody, or an IL-4 receptor binding fragment, mutein, or derivative of an IL-4 receptor binding antibody, to a patient afflicted with such a condition. Particular antibodies provided herein include human monoclonal antibodies. Certain of the antibodies inhibit both IL-4-induced and IL-13-induced biological activities.
    Type: Application
    Filed: November 4, 2004
    Publication date: May 26, 2005
    Inventors: Paul Carter, Hongxing Zhou
  • Patent number: 5759947
    Abstract: A bifunctional catalyst containing multimetal oxides, and a method for preparing the same, includes a support of a moulded mixture of silica and alumina in a weight ratio of 1:1.2-2.5, and upon the support is deposited 3-30% by weight of metal oxides based on the total weight of the catalyst. The metal elements of the metal oxides are at least two selected from transition metal of period 4 of the periodic table and lanthanide. The metal oxides of the catalyst exist in the state of non-composite oxides.
    Type: Grant
    Filed: March 18, 1996
    Date of Patent: June 2, 1998
    Inventor: Hongxing Zhou